Global Blood Group Typing Market

1 INTRODUCTION OF GLOBAL BLOOD GROUP TYPING MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BLOOD GROUP TYPING MARKET OUTLOOK
4.1 Overview

4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities

4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL BLOOD GROUP TYPING MARKET, BY TECHNIQUE
5.1 PCR-Based and Microarray Techniques
5.2 Assay-Based Techniques
5.3 Massively Parallel Sequencing
5.4 Other Techniques

6 GLOBAL BLOOD GROUP TYPING MARKET, BY PRODUCTS AND SERVICES
6.1 Consumables
6.1.1 Antisera Reagents
6.1.2 Red Blood Cell Reagents
6.1.3 Anti-Human Globulin Reagents
6.1.4 Blood Bank Saline

6.2 Instruments
6.3 Services

7 GLOBAL BLOOD GROUP TYPING MARKET, BY END USER
7.1 Hospitals
7.2 Clinical Laboratories
7.3 Blood Banks
7.4 Other End Users

8 GLOBAL BLOOD GROUP TYPING MARKET, BY TEST TYPE
8.1 Antibody Screening
8.2 HLA Typing
8.3 ABO Blood Tests
8.4 Cross-Matching Tests
8.5 Antigen Typing

9 GLOBAL BLOOD GROUP TYPING MARKET, BY GEOGRAPHY
9.1 Overview

9.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico

9.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe

9.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific

9.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina

9.6 Rest of the World Regional Market Estimates and Forecasts, 2012 - 2025

10 GLOBAL BLOOD GROUP TYPING MARKET COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES

11.1 Bio-Rad Laboratories, Inc.
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments

11.2 Beckman Coulter
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments

11.3 Grifols International, S.A.
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments

11.4 Immucor, Inc.
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments

11.5 Merck KGaA
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments

11.6 Novacyt Group
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments

11.7 Quotient, Ltd.
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments

11.8 Ortho Clinical Diagnostics, Inc.
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments

11.9 Bag Health Care GmbH
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Developments

11.10 Rapid Labs
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Developments

11.11 AXO Science
11.11.1 Overview
11.11.2 Financial Performance
11.11.3 Product Outlook
11.11.4 Key Developments

11.12 Agena Bioscience, Inc.
11.12.1 Overview
11.12.2 Financial Performance
11.12.3 Product Outlook
11.12.4 Key Developments

11.13 Day Medical SA
11.13.1 Overview
11.13.2 Financial Performance
11.13.3 Product Outlook
11.13.4 Key Developments

12 Appendix
12.1 Related Reports